{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T20:05:16Z","timestamp":1793390716286,"version":"4.5.0"},"reference-count":82,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,4,1]],"date-time":"2019-04-01T00:00:00Z","timestamp":1554076800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,4,1]],"date-time":"2019-04-01T00:00:00Z","timestamp":1554076800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Critical Reviews in Oncology\/Hematology"],"published-print":{"date-parts":[[2019,4]]},"DOI":"10.1016\/j.critrevonc.2019.02.001","type":"journal-article","created":{"date-parts":[[2019,2,10]],"date-time":"2019-02-10T18:46:43Z","timestamp":1549824403000},"page":"56-63","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":163,"special_numbering":"C","title":["Management of adverse effects\/toxicity of ibrutinib"],"prefix":"10.1016","volume":"136","author":[{"given":"Semra","family":"Paydas","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.critrevonc.2019.02.001_bib0005","doi-asserted-by":"crossref","first-page":"1940","DOI":"10.1182\/blood-2016-06-722991","article-title":"Atypical Pneumocystis jirovecii pneumonia in previously untreated patients with CLL on single agent ibrutinib","volume":"128","author":"Ahn","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2019.02.001_bib0010","doi-asserted-by":"crossref","first-page":"3592","DOI":"10.1182\/blood-2003-04-1142","article-title":"Tec regulates platelet activation by GPVI in the absence of Btk","volume":"102","author":"Atkinson","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2019.02.001_bib0015","doi-asserted-by":"crossref","first-page":"2612","DOI":"10.1182\/blood-2016-12-737346","article-title":"Impact of ibrutinib dose adherence on therapeutic efficacy in patients with previously treated CLL\/SLL","volume":"129","author":"Barr","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2019.02.001_bib0020","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1001\/jamadermatol.2016.0225","article-title":"Hair and nail changes during long-term therapy with ibrutinib for chronic lymphocytic leukemia","volume":"152","author":"Bitar","year":"2016","journal-title":"JAMA Dermatol."},{"key":"10.1016\/j.critrevonc.2019.02.001_bib0025","doi-asserted-by":"crossref","first-page":"1796","DOI":"10.3324\/haematol.2017.171041","article-title":"Characterization of atrial fibrillation adverse events reported in ibrutinib randomized controlled registration trials","volume":"102","author":"Brown","year":"2017","journal-title":"Haematologica"},{"key":"10.1016\/j.critrevonc.2019.02.001_bib0030","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1016\/S1470-2045(14)70335-3","article-title":"Safety and activity of ibrutinib plus rituximab for patients with high-risk chronic lymphocytic leukaemia: a single-arm, phase 2 study","volume":"15","author":"Burger","year":"2014","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.critrevonc.2019.02.001_bib0035","doi-asserted-by":"crossref","first-page":"2425","DOI":"10.1056\/NEJMoa1509388","article-title":"Ibrutinib as initial therapy for patients with chronic lymphocytic leukemia","volume":"373","author":"Burger","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.critrevonc.2019.02.001_bib0040","doi-asserted-by":"crossref","first-page":"2326","DOI":"10.1161\/ATVBAHA.115.306130","article-title":"Ibrutinib inhibits platelet integrin aIIbb3 outside-in signaling and thrombus stability but not adhesion to collagen","volume":"35","author":"Bye","year":"2015","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.critrevonc.2019.02.001_bib0045","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1056\/NEJMoa1215637","article-title":"Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia","volume":"369","author":"Byrd","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.critrevonc.2019.02.001_bib0050","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1056\/NEJMoa1400376","article-title":"Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia","volume":"371","author":"Byrd","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.critrevonc.2019.02.001_bib0055","doi-asserted-by":"crossref","first-page":"2497","DOI":"10.1182\/blood-2014-10-606038","article-title":"Three-year follow-up of treatment-naive and previously treated patients with CLL and SLL receiving single-agent ibrutinib","volume":"125","author":"Byrd","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2019.02.001_bib0060","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1182\/bloodadvances.2016001883","article-title":"Current understanding of bleeding with ibrutinib use: a systematic review and meta-analysis","volume":"12","author":"Caron","year":"2017","journal-title":"Blood Adv."},{"key":"10.1016\/j.critrevonc.2019.02.001_bib0065","first-page":"1","article-title":"Practical recommendations for the choice of anticoagulants in the management of patients with atrial fibrillation on ibrutinib","volume":"128","author":"Chai","year":"2017","journal-title":"Leuk. Lymphoma"},{"key":"10.1016\/j.critrevonc.2019.02.001_bib0070","doi-asserted-by":"crossref","first-page":"2450","DOI":"10.1182\/blood-2014-07-590323","article-title":"The impact of bleeding complications in patients receiving target-specific oral anticoagulants: a systematic review and meta-analysis","volume":"124","author":"Chai-Adisaksopha","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2019.02.001_bib0075","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/S1470-2045(15)00465-9","article-title":"Ibrutinib combined with bendamustine and rituximab compared with placebo, bendamustine, and rituximab for previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (HELIOS): a randomised, double-blind, phase 3 study","volume":"17","author":"Chanan-Khan","year":"2016","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.critrevonc.2019.02.001_bib0080","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1038\/leu.2013.358","article-title":"BTK inhibition targets in vivo CLL proliferation through its effects on B-cell receptor signaling activity","volume":"28","author":"Cheng","year":"2014","journal-title":"Leukaemia"},{"key":"10.1016\/j.critrevonc.2019.02.001_bib0085","first-page":"424","article-title":"Occult HBV reactivation induced by ibrutinib treatment: a case report","volume":"78","author":"de Jesus Ngoma","year":"2015","journal-title":"Acta Gastroenterol. Belg."},{"issue":"4","key":"10.1016\/j.critrevonc.2019.02.001_bib0090","doi-asserted-by":"crossref","first-page":"e00156","DOI":"10.1002\/prp2.156","article-title":"Effect of CYP3A perpetrators on ibrutinib exposure in healthy participants","volume":"3","author":"de Jong","year":"2015","journal-title":"Pharmacol. Res. Perspect."},{"key":"10.1016\/j.critrevonc.2019.02.001_bib0095","first-page":"1","article-title":"A drug\u2013drug interaction study of ibrutinib with moderate\/strong CYP3A inhibitors in patients with B-cell malignancies","volume":"30","author":"de Jong","year":"2018","journal-title":"Leuk. Lymphoma"},{"key":"10.1016\/j.critrevonc.2019.02.001_bib0100","doi-asserted-by":"crossref","first-page":"1629","DOI":"10.3324\/haematol.2017.164103","article-title":"Incidence and management of toxicity associated with ibrutinib and idelalisib: a practical approach","volume":"102","author":"de Weerdt","year":"2017","journal-title":"Haematologica"},{"key":"10.1016\/j.critrevonc.2019.02.001_bib0105","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1002\/cpt.419","article-title":"Ibrutinib dosing strategies based on interaction potential of CYP3A4 perpetrators using physiologically based pharmacokinetic modeling","volume":"100","author":"de Zwart","year":"2016","journal-title":"Clin. Pharmacol. Ther."},{"issue":"10020","key":"10.1016\/j.critrevonc.2019.02.001_bib0110","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1016\/S0140-6736(15)00667-4","article-title":"Ibrutinib versus temsirolimus in patients with relapsed or refractory mantle-cell lymphoma: an international, randomised, openlabel, phase 3 study","volume":"387","author":"Dreyling","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.critrevonc.2019.02.001_bib0115","unstructured":"European Medicines Agency, 2017. http:\/\/www.ema.europa.eudocsenGBdocumentlibraryEPARProductInformationhumanWC.pdf, pp. 1\u201337."},{"key":"10.1016\/j.critrevonc.2019.02.001_bib0120","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/S1470-2045(14)71182-9","article-title":"Ibrutinib for previously untreated and relapsed or refractory chronic lymphocytic leukaemia with TP53 aberrations: a phase 2, single-arm trial","volume":"16","author":"Farooqui","year":"2015","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.critrevonc.2019.02.001_bib0125","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1016\/j.amjmed.2016.06.045","article-title":"Causes of death and influencing factors in patients with atrial fibrillation","volume":"129","author":"Fauchier","year":"2016","journal-title":"Am. J. Med."},{"key":"10.1016\/j.critrevonc.2019.02.001_bib0130","unstructured":"FDA, 2015. [Internet]. http:\/\/www.accessdata.fda.govdrugsatfdadocslabel-slbl.pdf, pp. 1\u201326."},{"key":"10.1016\/j.critrevonc.2019.02.001_bib0135","first-page":"354","volume":"126","author":"Fihn","year":"2012","journal-title":"Circulation"},{"key":"10.1016\/j.critrevonc.2019.02.001_bib0140","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.3324\/haematol.2016.147900","article-title":"Ibrutinib for relapsed\/refractory chronic lymphocytic leukemia: a UK and Ireland analysis of outcomes in 315 patients","volume":"101","author":"Forum","year":"2016","journal-title":"Haematologica"},{"key":"10.1016\/j.critrevonc.2019.02.001_bib0145","doi-asserted-by":"crossref","first-page":"1955","DOI":"10.1182\/blood-2017-11-818286","article-title":"Early-onset invasive aspergillosis and other fungal infections in patients treated with ibrutinib","volume":"131","author":"Ghez","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2019.02.001_bib0150","doi-asserted-by":"crossref","first-page":"1987","DOI":"10.1182\/blood-2018-01-826495","article-title":"Risk of hepatitis B virus reactivation in patients treated with ibrutinib","volume":"131","author":"Hammond","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2019.02.001_bib0155","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1007\/s00277-016-2917-2","article-title":"Severe hepatitis B virus reactivation related to ibrutinib monotherapy","volume":"96","author":"Herishanu","year":"2017","journal-title":"Ann. Hematol."},{"key":"10.1016\/j.critrevonc.2019.02.001_bib0160","doi-asserted-by":"crossref","first-page":"6287","DOI":"10.1182\/blood-2011-01-328484","article-title":"Bruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765","volume":"117","author":"Herman","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2019.02.001_bib0165","doi-asserted-by":"crossref","first-page":"13075","DOI":"10.1073\/pnas.1004594107","article-title":"The Bruton tyrosine kinase inhibitor PCI-32765 blocks B cell activation and is efficacious in models of autoimmune disease and B-cell malignancy","volume":"107","author":"Honigberg","year":"2010","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.critrevonc.2019.02.001_bib0170","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1111\/bjh.14302","article-title":"Ibrutinib-associated rash: a single-centre experience of clinicopathological features and management","volume":"180","author":"Iberri","year":"2018","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.critrevonc.2019.02.001_bib0175","doi-asserted-by":"crossref","first-page":"2154","DOI":"10.1158\/1078-0432.CCR-16-1948","article-title":"Long-term follow-up of treatment with ibrutinib and rituximab in patients with high-risk chronic lymphocytic leukemia","volume":"23","author":"Jain","year":"2016","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.critrevonc.2019.02.001_bib0180","doi-asserted-by":"crossref","first-page":"2268","DOI":"10.1002\/cncr.30596","article-title":"Long-term outcomes for patients with chronic lymphocytic leukemia who discontinue ibrutinib","volume":"123","author":"Jain","year":"2017","journal-title":"Cancer"},{"key":"10.1016\/j.critrevonc.2019.02.001_bib0185","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1182\/blood-2014-12-617522","article-title":"Safety and activity of BTK inhibitor ibrutinib combined with ofatumumab in chronic lymphocytic leukemia: a phase 1b\/2 study","volume":"126","author":"Jaglowski","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2019.02.001_bib0190","unstructured":"Janssen. Imbruvica product monograph. Available at: https:\/\/www.janssen.com\/canada\/sites\/www_janssen_com_canada\/files\/product\/pdf\/imb09142015cpm_nc_185130.pdf (accessed 08.07.16)."},{"key":"10.1016\/j.critrevonc.2019.02.001_bib0195","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1111\/bjh.14660","article-title":"Use of anticoagulants and antiplatelet in patients with chronic lymphocytic leukaemia treated with single-agent ibrutinib","volume":"178","author":"Jones","year":"2017","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.critrevonc.2019.02.001_bib0200","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1038\/leu.2014.247","article-title":"Ibrutinib inhibits collagen-mediated but not ADP-mediated platelet aggregation","volume":"29","author":"Kamel","year":"2015","journal-title":"Leukaemia"},{"key":"10.1016\/j.critrevonc.2019.02.001_bib0205","doi-asserted-by":"crossref","first-page":"2893","DOI":"10.1093\/eurheartj\/ehw210","article-title":"ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS","volume":"37","author":"Kirchhof","year":"2016","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.critrevonc.2019.02.001_bib0210","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1016\/j.clml.2018.07.287","article-title":"Risk of major bleeding with ibrutinib","volume":"18","author":"Mock","year":"2018","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"10.1016\/j.critrevonc.2019.02.001_bib0215","doi-asserted-by":"crossref","first-page":"2581","DOI":"10.1182\/blood-2016-10-742437","article-title":"Ventricular arrhythmias and sudden death in patients taking ibrutinib","volume":"129","author":"Lampson","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2019.02.001_bib0220","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1182\/blood-2016-05-712828","article-title":"The risk of atrial fibrillation with ibrutinib use: a systematic review and meta-analysis","volume":"128","author":"Leong","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2019.02.001_bib0225","doi-asserted-by":"crossref","first-page":"3991","DOI":"10.1182\/blood-2014-06-583294","article-title":"Ibrutinib treatment affects collagen and von Willebrand factor-dependent platelet functions","volume":"124","author":"Levade","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2019.02.001_bib0230","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1111\/jth.12140","article-title":"Recommendations for thromboprophylaxis in the 2012 focused update of the ESC guidelines on atrial fibrillation: a commentary","volume":"11","author":"Lip","year":"2012","journal-title":"J. Thromb. Haemost."},{"key":"10.1016\/j.critrevonc.2019.02.001_bib0235","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1111\/jth.13386","article-title":"Bleeding risk assessment in atrial fibrillation: observations on the use and misuse of bleeding risk scores","volume":"14","author":"Lip","year":"2016","journal-title":"J. Thromb. Haemost."},{"key":"10.1016\/j.critrevonc.2019.02.001_bib0240","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.3324\/haematol.2015.126672","article-title":"Incidence and risk factors of bleeding-related adverse events in patients with chronic lymphocytic leukemia treated with ibrutinib","volume":"100","author":"Lipsky","year":"2015","journal-title":"Haematologica"},{"issue":"13 Suppl","key":"10.1016\/j.critrevonc.2019.02.001_bib0245","article-title":"Open label evaluation of ECG in patients with chronic lymphocytic leukemia (CLL) receiving ibrutinib monotherapy","volume":"31","author":"Loury","year":"2013","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2019.02.001_bib0250","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1053\/j.seminoncol.2016.02.008","article-title":"Bruton tyrosine kinase inhibition in chronic lymphocytic leukemia","volume":"43","author":"Maddocks","year":"2016","journal-title":"Semin. Oncol."},{"key":"10.1016\/j.critrevonc.2019.02.001_bib0255","doi-asserted-by":"crossref","first-page":"2199","DOI":"10.1182\/blood-2016-05-716977","article-title":"Outcomes of CLL patients treated with sequential kinase inhibitor therapy: a real world experience","volume":"128","author":"Mato","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2019.02.001_bib0260","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1093\/annonc\/mdx031","article-title":"Optimal sequencing of ibrutinib, idelalisib, and venetoclax in chronic lymphocytic leukemia: results from a multi-center study of 683 patients","volume":"28","author":"Mato","year":"2017","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.critrevonc.2019.02.001_bib0265","doi-asserted-by":"crossref","first-page":"3829","DOI":"10.1182\/blood-2014-10-604272","article-title":"Ibrutinib increases the risk of atrial fibrillation, potentially through inhibition of cardiac PI3K-Akt signaling","volume":"124","author":"McMullen","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2019.02.001_bib0270","doi-asserted-by":"crossref","first-page":"2243","DOI":"10.1182\/blood-2017-07-793786","article-title":"Ibrutinib for chronic graft-versus-host disease after failure of prior therapy","volume":"130","author":"Miklos","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2019.02.001_bib0275","doi-asserted-by":"crossref","first-page":"2224","DOI":"10.1182\/blood-2016-10-747345","article-title":"Targeting Bruton tyrosine kinase with ibrutinib in relapsed\/refractory marginal zone lymphoma","volume":"129","author":"Noy","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2019.02.001_bib0280","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/S1470-2045(13)70513-8","article-title":"Ibrutinib as initial therapy for elderly patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: an open-label, multicentre, phase 1b\/2 trial","volume":"15","author":"O\u2019Brien","year":"2014","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.critrevonc.2019.02.001_bib0285","first-page":"1663","article-title":"Rapid tyrosine phosphorylation and activation of Bruton's tyrosine\/Tec kinases in platelets induced by collagen binding or CD32 cross-linking","volume":"95","author":"Oda","year":"2000","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2019.02.001_bib0290","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1016\/j.amjcard.2016.12.007","article-title":"Comparison of HAS-BLED and HAS-BED versus CHADS2 and CHA2DS2VASC stroke and bleeding scores in patients with atrial fibrillation","volume":"119","author":"Poli","year":"2017","journal-title":"Am. J. Cardiol."},{"key":"10.1016\/j.critrevonc.2019.02.001_bib0295","unstructured":"Prescribing information: IMBRUVICA (ibrutinib) Capsules, for Oral Use. 2016. Available from: https:\/\/www.janssenmd.com\/pdf\/imbruvica\/PI-Imbruvica.pdf."},{"key":"10.1016\/j.critrevonc.2019.02.001_bib0300","doi-asserted-by":"crossref","first-page":"998","DOI":"10.2353\/ajpath.2009.090126","article-title":"Reduced phosphoinositide 3-kinase (p110a) activation increases the susceptibility to atrial fibrillation","volume":"175","author":"Pretorius","year":"2010","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.critrevonc.2019.02.001_bib0305","doi-asserted-by":"crossref","first-page":"5651","DOI":"10.1038\/sj.onc.1203958","article-title":"Signaling network of the Btk family kinases","volume":"19","author":"Qiu","year":"2000","journal-title":"Oncogene"},{"issue":"2","key":"10.1016\/j.critrevonc.2019.02.001_bib0310","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1038\/leu.2015.273","article-title":"Incidence and description of autoimmune cytopenias during treatment with ibrutinib for chronic lymphocytic leukemia","volume":"30","author":"Rogers","year":"2016","journal-title":"Leukemia"},{"key":"10.1016\/j.critrevonc.2019.02.001_bib0315","doi-asserted-by":"crossref","first-page":"1882","DOI":"10.1182\/blood-2018-02-832154","article-title":"Ibrutinib and fungus: an invasive concern","volume":"131","author":"Rogers","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2019.02.001_bib0320","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1056\/NEJM199510193331606","article-title":"Chronic lymphocytic leukaemia","volume":"333","author":"Rozman","year":"1995","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.critrevonc.2019.02.001_bib0325","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1124\/dmd.114.060061","article-title":"Absorption, metabolism, and excretion of oral (14)C radiolabeled ibrutinib: an open-label, phase I, single-dose study in healthy men","volume":"43","author":"Scheers","year":"2015","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.critrevonc.2019.02.001_bib0330","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1080\/10428194.2016.1257795","article-title":"Atrial fibrillation in patients with chronic lymphocytic leukemia (CLL)","volume":"58","author":"Shanafelt","year":"2017","journal-title":"Leuk. Lymphoma"},{"key":"10.1016\/j.critrevonc.2019.02.001_bib0335","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1007\/s11882-001-0065-8","article-title":"The clinical spectrum of Bruton's agammaglobulinemia","volume":"1","author":"Stewart","year":"2001","journal-title":"Curr. Allergy Asthma Rep."},{"key":"10.1016\/j.critrevonc.2019.02.001_bib0340","doi-asserted-by":"crossref","first-page":"2213","DOI":"10.1182\/blood-2015-04-639203","article-title":"Partial reconstitution of humoral immunity and fewer infections in patients with chronic lymphocytic leukemia treated with ibrutinib","volume":"126","author":"Sun","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2019.02.001_bib0345","first-page":"1","article-title":"Vigilance for ibrutinib-associated ventricular arrhythmias: rare but be aware","volume":"22","author":"Tam","year":"2018","journal-title":"Leuk. Lymphoma"},{"key":"10.1016\/j.critrevonc.2019.02.001_bib0350","doi-asserted-by":"crossref","first-page":"1554","DOI":"10.1080\/10428194.2017.1375110","article-title":"Cardiac side effects of bruton tyrosine kinase (BTK) inhibitors","volume":"59","author":"Tang","year":"2017","journal-title":"Leuk. Lymphoma"},{"key":"10.1016\/j.critrevonc.2019.02.001_bib0355","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1111\/bjh.14324","article-title":"Atrial fibrillation in CLL patients treated with ibrutinib. An international retrospective study","volume":"175","author":"Thompson","year":"2016","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.critrevonc.2019.02.001_bib0360","first-page":"847","article-title":"Ibrutinib, an approved tyrosine kinase inhibitor as a potential cause of recurrent polymorphic ventricular tachycardia","volume":"2","author":"Tomcsanyi","year":"2016","journal-title":"JACC: Clin. Electrophysiol."},{"key":"10.1016\/j.critrevonc.2019.02.001_bib0365","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1056\/NEJMoa1501548","article-title":"Ibrutinib in previously treated Waldenstrom's macroglobulinemia","volume":"372","author":"Treon","year":"2015","journal-title":"N. Engl. J Med."},{"key":"10.1016\/j.critrevonc.2019.02.001_bib0370","doi-asserted-by":"crossref","first-page":"254","DOI":"10.3324\/haematol.2015.138289","article-title":"Autoimmune cytopenias in patients with chronic lymphocytic leukemia treated with ibrutinib","volume":"101","author":"Vitale","year":"2016","journal-title":"Haematologica"},{"key":"10.1016\/j.critrevonc.2019.02.001_bib0375","first-page":"970","article-title":"Proposed algorithm for managing ibrutinib related atrial fibrillation","volume":"30","author":"Vrontikis","year":"2016","journal-title":"Oncology"},{"key":"10.1016\/j.critrevonc.2019.02.001_bib0380","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1056\/NEJMoa1306220","article-title":"Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma","volume":"369","author":"Wang","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.critrevonc.2019.02.001_bib0385","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1182\/blood-2015-03-635326","article-title":"Long term follow-up of MCL patients treated with single-agent ibrutinib: updated safety and efficacy results","volume":"126","author":"Wang","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2019.02.001_bib0390","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/S1470-2045(15)00438-6","article-title":"Ibrutinib in combination with rituximab in relapsed or refractory mantle cell lymphoma: a single-centre, open-label, phase 2 trial","volume":"17","author":"Wang","year":"2016","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.critrevonc.2019.02.001_bib0395","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.3324\/haematol.2014.119123","article-title":"The role of B-cell receptor inhibitors in the treatment of patients with chronic lymphocytic leukemia","volume":"100","author":"Wiestner","year":"2015","journal-title":"Haematologica"},{"key":"10.1016\/j.critrevonc.2019.02.001_bib0400","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.3324\/haematol.2016.144576","article-title":"Real-world results of ibrutinib in patients with relapsed or refractory chronic lymphocytic leukemia: data from 95 consecutive patients treated in a compassionate use program","volume":"101","author":"Winqvist","year":"2016","journal-title":"Haematologica"},{"issue":"Suppl 3","key":"10.1016\/j.critrevonc.2019.02.001_bib0405","article-title":"Proarrhythmic effects of ibrutinib, a clinically approved inhibitor of Bruton's tyrosine kinase (BTK) used in cancer therapy [abstract]","volume":"132","author":"Yang","year":"2015","journal-title":"Circulation"},{"key":"10.1016\/j.critrevonc.2019.02.001_bib0410","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.clml.2016.09.010","article-title":"Risk of atrial fibrillation and bleeding diathesis associated with ibrutinib treatment: a systematic review and pooled analysis of four randomized controlled trials","volume":"17","author":"Yun","year":"2017","journal-title":"Clin. Lymphoma Myeloma Leuk."}],"container-title":["Critical Reviews in Oncology\/Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842818303901?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842818303901?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T19:28:03Z","timestamp":1760902083000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1040842818303901"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,4]]},"references-count":82,"alternative-id":["S1040842818303901"],"URL":"https:\/\/doi.org\/10.1016\/j.critrevonc.2019.02.001","relation":{},"ISSN":["1040-8428"],"issn-type":[{"value":"1040-8428","type":"print"}],"subject":[],"published":{"date-parts":[[2019,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Management of adverse effects\/toxicity of ibrutinib","name":"articletitle","label":"Article Title"},{"value":"Critical Reviews in Oncology\/Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.critrevonc.2019.02.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}